<DOC>
	<DOCNO>NCT01892501</DOCNO>
	<brief_summary>Impact screen node mediastinal PET , different time management cancer disease , remain unclear . Benefits combine PET puncture echoendoscopy diagnosis subsequent therapeutic management evaluate different context . We would like demonstrate clinical utility association replace invasive diagnostic procedure assess impact puncture possible modification therapeutic management . It single center prospective diagnostic assessment</brief_summary>
	<brief_title>Feasability Study Contribution Guided Puncture With Echoendoscopy</brief_title>
	<detailed_description>Main objective : Assess performance ( term sensitivity ) guide punction echoendoscopy characterization hypermetabolic mediastinal lymph node PET , context New cancer cancer recurrence . Conduct study : When patient PET scan show hypermetabolic mediastinal lymph node low , middle posterior , case present multidisciplinary meeting ( PCR # 1 ) , definition diagnostic strategy : Approved indication achieve biopsy surgically histological documentation mediastinal lymph node obvious impact treatment decision . We distinguish two group patient base feasibility surgical procedure : 1 . Group A biopsy surgically feasible 2 . Group B : biopsy surgery perform ( medical contraindication anesthetic ) moment , definition therapeutic strategy decide absence histological documentation : - Surgery outset - Chemotherapy oncological treatment - Supports non-oncological benign disease suspect - No treatment . EUS perform oesophageal two patient group two group patient ( within maximum period six week PET scan ) , general anesthesia endoscopic control . According pathological finding , therapeutic strategy define second PCR ( PCR # 2 ) , assess impact puncture : - Surgery outset - Chemotherapy oncological treatment - Supports non-oncological benign pathology document - No treatment - Selecting another surgical diagnostic procedure ( non-contributory income ) . A patient monitoring conduct 12 month . The clinical radiological data carry standard care patient collect . Achieving thoracoabdominopelvien scanner ( TAP ) 1 year characterize evolution disease mark end study patient . For patient negative biopsy , monitor involve scanner TAP 6 month 12 month consultation oncologist .</detailed_description>
	<criteria>1 . Any patient PET show one hypermetabolic lymphadenopathy middle mediastinum and/or lower and/or posterior , require diagnostic certainty support . 2 . PET scan perform particular : Pretreatment assessment thoracic extrathoracic malignancy ( patient without history cancer ) . Evaluation response treatment refer oncological . Suspicion relapse patient personal history thoracic extrathoracic malignancy . 3 . PET , result positive : For abovecentimenter lymph node short axis : great result equal background hepatic noise . For subcentimenter lymph node small axis : great result background hepatic noise 4 . Patient indication diagnostic procedure surgically ( whether realize ) 5 . Lymph node ( ) available ( ) puncture EUS esophageal , technically feasible esophageal puncture ( without vascular structure recusantes ) 6 . Age ≥ 18 year . 7 . PET scan perform within 6 week EUS 8 . Platelets ≥ 70 000/mm3 ; TP ≥ 60 % . 9 . Patient childbearing age negative pregnancy test / contraception . 10 . Patient give inform consent sign . 11 . Patient affiliate social security scheme . Contraindication ( ) Director ( ) achieve EUS . Balance adverse anesthetic ( allow general anesthetic ) . Esophageal stenosis . Coagulation disorder . Pregnant lactating woman . Unable undergo medical monitoring test geographical , social psychological reason . Private patient freedom major subject measure legal protection unable consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Mediastinal lymphadenopathy</keyword>
	<keyword>PET CT 18FDG</keyword>
	<keyword>EUS</keyword>
</DOC>